Elsevier

Progress in Cardiovascular Diseases

Volume 60, Issue 3, November–December 2017, Pages 394-404
Progress in Cardiovascular Diseases

Mitral valve repair: Robotic and other minimally invasive approaches

https://doi.org/10.1016/j.pcad.2017.11.002Get rights and content
Under a Creative Commons license
open access

Abstract

Robotic and minimally invasive mitral valve (MV) procedures have been performed with increasing frequency over time. These alternatives offer similar efficacy to that achieved via standard median sternotomy, particularly in large volume centers, along with low perioperative morbidity and mortality rates. Moreover, patient acceptance is oftentimes increased due to less postoperative pain and shorter recovery times, as well as superior cosmetic results. However, these techniques are technically complex and associated with a significant learning curve. The following review offers an overview of the most relevant aspects related to minimally invasive and robotic MV repair. Although these techniques are well established in referral centers, future innovations should concentrate on decreasing complexity and improving reproducibility of these procedures.

Keywords

Minimally invasive
Robotic surgery
Mitral valve
Repair

Abbreviations and Acronyms

2D
Two-dimensional
3D
Three-dimensional
AF
Atrial fibrillation
AML
Anterior mitral leaflet
AR
Aortic regurgitation
ASD
Atrial septal defect
CPB
Cardiopulmonary bypass
ICS
Intercostal space
LV
Left ventricular
LVEF
Left ventricular ejection fraction
LVESD
Left ventricular end systolic dimension
MR
Mitral regurgitation
MV
Mitral valve
PML
Posterior mitral leaflet
PTFE
Polytetrafluorethylene
SVC
Superior vena cava
TEE
Transesophageal echocardiography

Cited by (0)

Statement of conflict of interest: see page 402.

Author disclosures: Dr. Gillinov is a consultant for CryoLife Technologies, Edwards Lifesciences, Medtronic, St. Jude Medical, Abbott Laboratories, and Atricure. He receives research funding from Abbott. Dr. Borger is a consultant for Edwards Lifesciences, Medtronic, LivaNova and CryoLife. No other author has a financial relationship with industry to report.